×
About 1,565 results

ALLMedicine™ Lymphoblastic Lymphoma Center

Research & Reviews  471 results

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refr...
https://clinicaltrials.gov/ct2/show/NCT03384654

Aug 12th, 2022 - Screening for eligible participants will be performed within 21 days before administration of the study drug. Participants with B-cell ALL/LL will receive treatment until disease progression, unacceptable toxicity or achievement of CR followed by ...

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT03914625

Aug 12th, 2022 - PRIMARY OBJECTIVES: I. To determine in a randomized manner if the addition of 2 cycles of blinatumomab to standard therapy improves disease-free survival (DFS) in patients with standard risk (SR) B-ALL and higher risk features (SR-High), and patie...

SOHO State of the Art Updates and Next Questions | Novel Approaches to Pediatric T-cell...
https://doi.org/10.1016/j.clml.2022.07.010
Clinical Lymphoma, Myeloma & Leukemia; Summers RJ, Teachey DT

Aug 9th, 2022 - While outcomes for children with T-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LL) have improved significantly with contemporary therapy, outcomes for patients with relapsed or refractory (r/r) disease remain dismal. ...

An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)
https://clinicaltrials.gov/ct2/show/NCT04145531

Aug 5th, 2022 - This is an open-label, multicenter, dose confirmation, and PK study of JZP-458 in patients (of any age) with ALL/LBL who are hypersensitive to E. coli-derived asparaginases (allergic reaction or silent inactivation). This study is designed to asse...

Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05303792

Aug 3rd, 2022 - PRIMARY OBJECTIVE: I. To compare undetectable measurable residual disease (MRD) event-free survival (EFS) rate of the experimental arm (A) to standard arm (B) with EFS defined as time from randomization to occurrence of an event. SECONDARY OBJECTI...

see more →

Drugs  5 results see all →

Clinicaltrials.gov  105 results

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT03914625

Aug 12th, 2022 - PRIMARY OBJECTIVES: I. To determine in a randomized manner if the addition of 2 cycles of blinatumomab to standard therapy improves disease-free survival (DFS) in patients with standard risk (SR) B-ALL and higher risk features (SR-High), and patie...

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refr...
https://clinicaltrials.gov/ct2/show/NCT03384654

Aug 12th, 2022 - Screening for eligible participants will be performed within 21 days before administration of the study drug. Participants with B-cell ALL/LL will receive treatment until disease progression, unacceptable toxicity or achievement of CR followed by ...

An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)
https://clinicaltrials.gov/ct2/show/NCT04145531

Aug 5th, 2022 - This is an open-label, multicenter, dose confirmation, and PK study of JZP-458 in patients (of any age) with ALL/LBL who are hypersensitive to E. coli-derived asparaginases (allergic reaction or silent inactivation). This study is designed to asse...

Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05303792

Aug 3rd, 2022 - PRIMARY OBJECTIVE: I. To compare undetectable measurable residual disease (MRD) event-free survival (EFS) rate of the experimental arm (A) to standard arm (B) with EFS defined as time from randomization to occurrence of an event. SECONDARY OBJECTI...

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
https://clinicaltrials.gov/ct2/show/NCT00408005

Jul 28th, 2022 - PRIMARY OBJECTIVES: I. To determine, through randomization, the relative safety and efficacy of the addition of nelarabine (Compound 506U78) to augmented Berlin-Frankfurt-Münster (BFM) therapy (Regimen C, Children's Cancer Group [CCG]-1961). II. T...

see more →

News  45 results

Bortezomib Improves OS in Newly Diagnosed T-Cell Lymphoblastic Leukemia and Lymphoma
https://www.onclive.com/view/bortezomib-improves-os-in-newly-diagnosed-t-cell-lymphoblastic-leukemia-and-lymphoma

Apr 18th, 2022 - The addition of bortezomib (Velcade) to chemotherapy improved survival rates in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma (T-LL), according to data from the phase 3 AALL1231 trial (NCT02112916) published in the J...

2021 Approvals Expand Access to Care for Patients Across Tumor Types
https://www.onclive.com/view/2021-approvals-expand-access-to-care-for-patients-across-tumor-types

Mar 10th, 2022 - Last year marked the 50th anniversary of the National Cancer Act of 1971, a landmark legislation that committed to funding biomedical research, establishing oncology training programs, and building a nationwide network of cancer treatment centers....

Children With Cancer At Higher Risk for Severe Illness from COVID-19
https://www.onclive.com/view/children-with-cancer-at-higher-risk-for-severe-illness-from-covid-19

Oct 22nd, 2021 - Approximately 20% of pediatric patients with cancer infected with COVID-19 experienced severe illness, according to data published in The Lancet Oncology. Furthermore, deaths due to the infection were proportionally higher in this patient populati...

Kids With Cancer More Likely to Develop Severe COVID
https://www.medpagetoday.com/hematologyoncology/othercancers/94225

Aug 26th, 2021 - Children and adolescents with cancer and SARS-CoV-2 infection were more likely to develop severe and critical cases of COVID-19 compared with the general pediatric population, according to a global cohort study. Of children with cancer who contrac...

FDA Approves New Asparaginase Product for Leukemia
https://www.medscape.com/viewarticle/954149

Jul 2nd, 2021 - The US Food and Drug Administration (FDA) has approved a new version of asparaginase for use in children and adults who have developed hypersensitivity to asparaginase derived from Escherichia coli. The new product is Jazz Pharmaceutical's Rylaze ...

see more →